Asia
Companies are cutting the price of some medications by an average of 53% in order to qualify for the bulk-buy program in China, Reuters reported.
Celltrion’s chairman Jung Jin Seo announced at last week’s JP Morgan Healthcare Conference the company’s strategy for the next decade.
First drug product facility in Europe to complement WuXi Biologics’ existing commercial manufacturing capacities
There were plenty of clinical trial announcements this week. Here’s a look.
TCG Lifesciences, a company promoted by New York based Purnendu Chatterjee Group, has announced the induction of Chris Senanayake, as Chief Scientific Officer responsible for delivering highest quality scientific solutions and innovations to its global client base.
Here’s a look at the top 10 companies noted in the BioSpace Ideal Employer 2019 survey for being the most innovative and what they’ve been up to recently.
The biosimilar candidate, IBI305, completed a Phase III study in China and was granted Priority Review by that country’s National Medical Products Administration.
“We are excited to sign this acquisition agreement with Bayer, allowing us to have quick access to high-quality drug product manufacturing capacities and capabilities,” said Chris Chen, chief executive officer of WuXi Biologics.
The two companies joined their consumer health businesses in order to give the parent companies more maneuverability to focus on the pharmaceuticals.
Companies from across the globe provide updates to their business and pipeline.
PRESS RELEASES